H.C. Wainwright raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $22 from $21 and keeps a Buy rating on the shares following the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- ORIC Pharmaceuticals: A Promising Buy with Upcoming Data Catalysts and Competitive Safety Profile
- ORIC Pharmaceuticals Reports Q1 2025 Progress and Plans
- Oncology stocks ‘bearing the brunt’ of Prasad news, says Oppenheimer
- Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer
- Buy Rating for Oric Pharmaceuticals: Promising Pipeline and Strong Financial Position